Article-processing charge discount for AORTIC members

Infectious Agents and Cancer are proudly affiliated with the African Organization for Research and Training in Cancer (AORTIC).  All members of AORTIC receive a 15% discount on the article-processing charge for each article accepted for publication.  This discount can be requested during the submission process and will be verified before being applied.  Standard waiver rules apply for low-income countries.


View all articles

  1. Review

    Simian virus 40 in humans

    Fernanda Martini, Alfredo Corallini, Veronica Balatti, Silvia Sabbioni, Cecilia Pancaldi and Mauro Tognon

    Published on: 9 July 2007

View all articles

Latest Tweets


Franco M Buonaguro, Istituto Nazionale Tumori, Naples, Italy

Sam M Mbulaiteye, National Cancer Institute, Bethesda, USA

Aims and scope

Infectious Agents and Cancer is an open access, peer-reviewed online journal that encompasses all aspects of basic, clinical and translational research providing an insight into the association between chronic infections and cancer.

The journal welcomes submissions in the pathogen-related cancer areas and other related topics, in particular:

• HPV and anogenital cancers, as well as head and neck cancers;
• EBV and Burkitt lymphoma;
• HCV/HBV and hepatocellular carcinoma as well as lymphoproliferative diseases;
• HHV8 and Kaposi sarcoma;
• HTLV and leukemia;
• Cancers in Low- and Middle-income countries.

There are established links between specific chronic infections and cancer. Recent advances in genomic and proteomic technologies have accelerated the discovery of novel pathogens, cancer antigens and the molecular pathways involved in disease progression. Several new fields are developing very rapidly, in particular the application of immunogenomics and pharmacogenomics to fight specific cancers, targeting immuno-tolerated cellular/viral molecules by immuno and drug therapy. Infectious Agents and Cancer covers all these areas of biomedical research and any other topics pertinent to the development of therapies for chronic infections and cancer.